Medesis Pharma is listed on Euronext Growth Paris since February 12th, 2021.
This « Investors » section gathers information for shareholders and investors.

View the opening bell ceremony on Euronext Growth Paris for the first day of trading of Medesis Pharma’s shares:

Financial press release 


Treatment of alzheimer’s disease : ANSM authorizes Medesis Pharma Phase II clinical trial – September 21, 2021
🇬🇧
2021 half-year financial and business report – September 16, 2021  🇫🇷
Medesis Pharma announces a joint European patent with TRANSGENE – September 1, 2021 🇬🇧
Nanomanganese developement program repositionned outside of EU after ANSM authorisation denial – August 26, 2021 🇬🇧
The development plan of the drug candidate for the treatment of Huntington’s Disease receives a positive opinion from the European Medicines Agency – June 3, 2021 🇬🇧
Initiation of analyst coverage by Invest Securities – May 7, 2021 🇫🇷
Availability of the 2020 Annual Financial Report – April 28, 2021 🇫🇷
Annual results and 2021 outlook – April 14, 2021 🇫🇷
Description of the share buyback program and implementation of a liquidity contract – March 12, 2021 🇫🇷
Medesis Pharma raises €7.35m following a very successful IPO on Euronext Growth Paris – Feb. 10, 2021 🇫🇷
Medesis Pharma launches its initial public offering on Euronext Growth Paris – Jan 26, 2021 🇫🇷

 

Documents & Financial reports (in french only)


2021 HY Financial report – October 7, 2021
2020 Financial report April 28, 2021
Information Document – IPO on Euronext Growth Paris – Jan. 26, 2021
Investors presentation – IPO on Euronext Growth Paris  – Jan. 26, 2021

 

Share information


 

Share information and price

 

 

  • Name: MEDESIS PHARMA
  • Market: Euronext Growth Paris
  • ISIN code: FR0010844464
  • Mnemo: ALMDP
  • Type of shares: Ordinary shares
  • PEA & PEA PME eligibility : Yes
  • ICB Classification: 4573 – Biotechnology
  • LEI code: 969500C15M96P00UR648


Ownership

As of Feb. 12, 2021

Nb of shares & voting rights

% of ownership and voting rights

JC Maurel (Founder, Chairman of the Executive Board) 429 889 9,2 %
Corporate officers and employees 1 017 515 21,7 %
Other historical shareholders 2 351 842 50,2 %
Float 883 492 18,9 %
Total 4 682 738 100,0 %

 

Financial calendar


This calendar will be provided shortly. It is provided for information purposes only and is subject to change if the Company deems it necessary.

 

Regulated informations


The sections concern the regulated information made available to the public and shareholders in connection with the listing of Medesis Pharma on Euronext Growth Paris.

Monthly number of shares and voting rights

Total number of shares Total number of voting rights
Feb. 12, 2021
(calculated on a fully-diluted basis)

4 682 738

4 682 738

June 30, 2021

4 360 219

6 768 795

July 31, 2021

4 360 219

6  768  795

August 31, 2021

4 360 219

6 742 278

September 30, 2021

4 360 219

6 641 836

 

Contacts


Medesis Pharma
avenue du Golf, L’Orée des Mas Les Cyprès, 34670 Baillargues, France
Tel: +33 4 67 10 71 61
contact@medesispharma.com

Financial communication

CALYPTUS
55, rue des Petites Ecuries – 75010 Paris
+33 1 53 65 68 68
medesispharma@calyptus.net

Listing sponsor

INVEST CORPORATE FINANCE
73, boulevard Haussmann – 75008 Paris
+33 1 70 98 39 40

Registered shareholder account holder:

CACEIS CORPORATE TRUST
14, rue Rouget de Lisle – 92130 Issy-les-Moulineaux
+33 1 57 78 00 00

 

For any additional information or to subscribe to the mailing-list to receive financial press releases, please complete the online form.